Whitepapers on Advancing Stem Cell Therapies
It's hard to keep track of all the stem cell advances each month. That's why we summarize the month's news, events and upcoming dates to remember. You can subscribe to receive these newsletters each month by RSS feed or by email.
Each scientific publication by our grantees describes an advance that could ultimately lead to new therapies.
Our annual report describes research advances, tells patient stories and proves insights about CIRM's impact on regenerative medicine from our chair and president.
- 2018 Annual Report
- 2017 Annual Report
- 2016 Annual Report
- 2015 Annual Report
- 2014 Annual Report [pdf]
Our workshops bring together experts in areas we think are going to be important in the development of new stem cell-based therapies.
Our efforts are guided by a set of clear goals laid out in our strategic plan, which we update every few years to reflect changes in the field.
- Strategic Plan 2016 and Beyond [pdf]
- Scientific Strategic Plan (May 2012) [pdf]
- Scientific Strategic Plan (October 2009) [pdf]
- Scientific Strategic Plan (December 2006) [pdf]
Our staff members publish regularly in high-profile journals where their insights help guide the field.
On June 25, 2013, The California Institute for Regenerative Medicine (CIRM), the Alliance for Regenerative Medicine (ARM), and the Cell Therapy Catapult (Catapult) convened a roundtable on June 25, 2013 to define technological challenges and identify potential solutions in three key areas:
- Manufacturing clinical-grade cell products derived from stem cells
- Characterizing the cell product
- Imaging cells post transplantation.
This white paper summarizes the proceedings from the roundtable and highlights key recommendations
In June 2014, The California Institute for Regenerative Medicine (CIRM) convened a workshop that followed up on the 2013 Key Tools and Technology Hurdles Roundtable. The 2014 workshop further discussed technological challenges and included a proposal for a CIRM sponsored Manufacturing Center of Excellence. This white paper summarizes the proceedings from the workshop and highlights key discourse.
We periodically commission reports by outside experts to clarify the impact of the agency on health care and the economy and to assess our effectiveness.
Investing in translational research to produce clinical, commercial and financial outcomes (2013) [pdf]
Updated economic impact report (2012) [pdf]
Report of the CIRM External Advisory Committee [pdf]
Coverage, Cost-Control Mechanisms, and Financial Risk-Sharing Alternatives of High-Cost Health Care Technologies [pdf]
Supporting Diversity in Research Participation: A Framework for Action [pdf]
Economic Impact of Research Funded by the California Institute for Regenerative Medicine (2010) [pdf]
We are proud of our record of fiscal responsibility. Our funding for administrative costs remains below 6% of our total expenses each year. These yearly financial statements provide details about where our money is spent.
2006/2007 Financial Statement [pdf]
2006/2007 Financial Supplement [pdf]
2007/2008 Financial Statement [pdf]
2007/2008 Financial Supplement [pdf]
2008/2009 Financial Statement [pdf]
2008/2009 Financial Supplement [pdf]
2009/2010 Financial Statement [pdf]
2009/2010 Financial Supplement [pdf]
2010/2011 Financial Statement [pdf]
2010/2011 Financial Supplement [pdf]
2011/2012 Financial Statement [pdf]
2011/2012 Financial Supplement [pdf]
2012/2013 Financial Statement [pdf]
2012/2013 Financial Supplement [pdf]
2013/2014 Financial Statement [pdf]
2013/2014 Financial Supplement [pdf]
2014/2015 Financial Statement [pdf]
2014/2015 Financial Supplement [pdf]
2015/2016 Financial Statement [pdf]
2015/2016 Financial Supplement [pdf]